Pfizer’s $43B Seagen Buy Starts to Pay Off with Adcetris Phase III Data

Pfizer has released results for the Phase III ECHELON-3 study, demonstrating that the antibody-drug conjugate (ADC) Adcetris significantly boosted survival in patients with relapsed/refractory diffuse large B-cell lymphoma when used with lenalidomide and rituximab. Originally developed by Seagen in collaboration with Takeda, Adcetris is an ADC that targets the CD30 surface protein.